Enhanced Immunogenicity of Self-Amplifying RNA Vaccines Against Influenza

Study Background and Research Question

Seasonal influenza remains a significant global health concern, with annual epidemics causing substantial morbidity and mortality. While mRNA vaccines have achieved remarkable success in recent years, clinical data reveal persistent challenges in eliciting robust immune responses against certain influenza subtypes, particularly influenza B virus (IBV). This limitation underscores the need to optimize RNA vaccine platforms for broader and more effective protection. The central research question addressed by Mengting Huang et al. (2026) is whether alternative RNA modalities, including self-amplifying RNA (saRNA) and circular RNA (circRNA), can overcome the immunogenicity constraints of conventional mRNA vaccines and provide improved efficacy across multiple influenza subtypes.

Key Innovation from the Reference Study

The study introduces a comprehensive, head-to-head evaluation of three RNA vaccine approaches: (1) nucleoside-modified mRNA, (2) self-amplifying RNA, and (3) circular RNA. Notably, the use of self-amplifying RNA as a vaccine platform represents a significant advance. This modality leverages an RNA replicon, enabling intracellular amplification of vaccine-encoded antigen and potentially amplifying immune responses while reducing required dose. The authors systematically optimized hemagglutinin (HA) antigen expression and assessed immunogenicity and protective efficacy in murine models. The design specifically addresses the practical challenge of low immunogenicity and transient responses observed with standard mRNA vaccines targeting IBV.

Methods and Experimental Design Insights

The research employed sequence-optimized RNA constructs encoding influenza HA antigens from WHO-recommended strains. Three vaccine platforms were directly compared:

• Nucleoside-modified mRNA: Standard mRNA with modified nucleosides, designed to minimize innate immune activation and improve translation.
• Self-amplifying RNA (saRNA): RNA construct encoding antigen and replicase, allowing intracellular RNA amplification.
• Circular RNA (circRNA): Covalently closed RNA, hypothesized to confer greater stability and persistence.

Murine models received low-dose (0.1 μg) mono- or trivalent vaccines. Humoral immune responses were quantified via antibody titers, while protective efficacy was assessed through survival following homologous viral challenge. The quadrivalent inactivated vaccine (QIV, 2 μg) served as a conventional comparator. Long-term antibody monitoring extended up to 20 weeks, providing insight into the durability of vaccine-induced immunity. Safety was evaluated through body weight monitoring and serum biochemical analysis.

Protocol Parameters

• Vaccine dose: 0.1 μg per mouse for mono- and trivalent RNA vaccines; 2 μg for QIV comparator.
• Antigen target: HA proteins of WHO-recommended influenza A and B strains.
• Immunization schedule: Single-dose administration; monitoring of humoral response up to 20 weeks post-immunization.
• Challenge protocol: Homologous viral challenge post-immunization to assess protection.
• Safety monitoring: Serial measurement of body weight and serum biochemistry following vaccination.

Core Findings and Why They Matter

The comparative analysis revealed several critical findings:

• Influenza A protection: Both mono- and trivalent nucleoside-modified mRNA vaccines, even at low 0.1 μg doses, induced robust antibody responses and conferred complete protection against homologous influenza A challenge. These vaccines outperformed the higher-dose (2 μg) QIV comparator in murine models.
• Influenza B challenge: In contrast, at equivalent low doses, IBV mRNA vaccines failed to elicit detectable antibody responses and provided no significant protection, mirroring suboptimal immunogenicity observed in human vaccination studies.
• Self-amplifying RNA (saRNA) advantage: The trivalent saRNA vaccine, administered at 0.1 μg, achieved robust humoral immunity and complete protection against IBV challenge—whereas mRNA vaccination resulted in only 14% survival according to the reference study.
• Durable immunity: Antibody titers in saRNA-vaccinated mice remained high over 20 weeks, indicating greater durability compared to conventional mRNA and circRNA platforms.
• Safety: No abnormal changes in body weight or serum biochemistry were detected across vaccine groups, supporting a favorable safety profile for the RNA modalities tested.

These findings underscore the potential of self-amplifying RNA to address the immunogenicity bottleneck for IBV and highlight its capacity for dose-sparing, which could be critical for scalable vaccine production and deployment.

Limitations and Transferability

While the study robustly demonstrates the advantages of saRNA vaccines in murine models, several limitations merit consideration. First, the translatability of mouse immune responses to humans remains uncertain, particularly for novel RNA modalities. Second, the study focuses on homologous viral challenge, and the breadth of cross-protection against antigenically drifted strains was not addressed. Third, while nucleoside modifications are known to improve translational fidelity and reduce innate immune activation, the exact molecular mechanisms underlying the superior performance of saRNA—such as potential effects on RNA secondary structure stabilization or epitranscriptomic regulation—require further elucidation. Finally, large-scale manufacturing and delivery logistics, especially for saRNA, have not been fully explored in this work.

Why this cross-domain matters, maturity, and limitations

The investigation bridges the domains of RNA modification research and applied vaccinology. By leveraging advances in the understanding of the C-glycoside isomer of uridine and related modified nucleosides, the study demonstrates how molecular engineering of RNA can directly impact vaccine immunogenicity and durability. However, the clinical maturity of saRNA vaccines lags behind that of conventional mRNA platforms, and further preclinical and clinical studies will be required to confirm efficacy, safety, and manufacturability at scale.

Comparison with Existing Internal Articles

Currently, no internal articles provide a comparable, systematic evaluation of RNA vaccine platforms across influenza subtypes, particularly with respect to self-amplifying RNA and its impact on IBV protection. Previous resources have generally focused on the mechanism of RNA modification and translational fidelity, but not on comparative vaccine efficacy in vivo. This study fills a critical gap by linking RNA design choices with real-world immunogenicity outcomes across multiple influenza strains.

Research Support Resources

Researchers wishing to explore the influence of RNA modifications on vaccine performance or RNA biology can utilize reference compounds such as β-Pseudouridine (SKU B8649). As the most abundant RNA modification in non-coding RNA, β-Pseudouridine is a C-glycoside isomer of uridine known to stabilize local RNA structures and modulate translational control. Its use as an RNA research reagent may support mechanistic studies and workflow optimization in the context of RNA vaccine development and epitranscriptomic regulation. For additional technical details, the product information offers relevant solubility, handling, and storage instructions.